When you squeeze a balloon, the air goes somewhere. Same with the cost of drugs. PRECISIONvalue expert Andrew Cournoyer, SVP of the Access Experience Team, explains the anticipated fallout from the Inflation Reduction Act in this 90-second video.
Biosimilars deliver dramatic reductions in drug costs—and the Inflation Reduction Act is supposed to encourage their uptake. But lower prices mean lower reimbursement, disincentivizing providers. PRECISIONvalue expert Amy Martin explains how in this 2-minute video.
How will the Inflation Reduction Act effect manufacturers of both originator drugs and biosimilars? According to PRECISIONvalue expert Amy Martin, a range of unintended consequences may impact pricing, innovation—and ultimately the therapies available to patients. Watch this short video to see why.
PRECISION is named a RECOGNIZED INNOVATOR twice in PM360 Magazine’s 2023 Innovators Issue for our Access Genius Insights and Navigator365 Core and Cx Benchmark technologies.
Access Genius combines best-in-class technology and unmatched data synthesis in a smart pharmaceutical market access messaging platform.
The Navigator365 suite of HCP insight products provide the tools and evidence clients need to answer key business questions and deliver a signature brand experience for their customers and patients.
Read more about how these innovative technologies in PM360’s Innovators Issue HERE.
Three Precision agencies – PRECISIONvalue, PRECISIONeffect and PRECISIONscientia – each rank as one of MM+M’s Top 100 North American healthcare agencies of 2023.
Bethesda, Md., April 12, 2023 — Precision Value & Health, the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, today announced that it has acquired Makara Health, a UK-based international healthcare communications agency. The move will expand Precision’s European footprint and reinforce the company’s market growth position with its core capabilities in Europe. Founded in 2013, Makara has capabilities in learning and development, medical and patient education, PR and brand promotion, offering its diverse roster of healthcare client companies high-quality, strategic, scientifically robust programs, as well as creative delivery solutions.
With this acquisition, Makara becomes part of the Precision Value & Health team. The Makara team will work closely with PRECISIONscientia, an agency dedicated to delivering medical and scientific communications that expertly interpret and translate the science of medicine.
BETHESDA, MD, March 14, 2023 – Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointment of John Hubbard, PhD, as Chairman of its Board of Directors.
“We are thrilled to welcome John to our Board. He is a highly regarded leader in the pharmaceutical industry with extensive experience in clinical development and operations, strategic planning and business development,” said Mark Clein, Chief Executive Officer of Precision Medicine Group. “His impressive qualifications make him uniquely qualified to appreciate the breadth of services offered across our organization and to provide valuable insight as we continue to expand our global footprint and integrated capabilities.”
Stern IR, part of Precision Value & Health, enhances market leadership position by integrating IR expertise, deep biotech knowledge, and ESG solutions to bring substantive value to clients. ESG Expert Molly Podolefsky, PhD, to lead complementary new ESG capability
NEW YORK, March 2, 2023 — Stern IR, Inc., a Precision Value & Health company, today announced the launch of its new environmental, social, and governance (ESG) advisory practice. The addition of the ESG practice will deliver a suite of solutions, including materiality assessments, ESG strategy and roadmap development, reporting, and communications packages that are well integrated with Stern’s core investor relations (IR) competencies. These complementary ESG solutions are designed to meet the evolving IR needs of biotechnology and healthcare companies, which increasingly involve and are influenced by ESG considerations and factors with ESG rapidly becoming a core component of best-in-class IR.
QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D)
QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning and R&D productivity
Frederick, MD – January 24, 2023 Precision for Medicine, the first global, precision medicine clinical research services organization, today announced the strategic acquisition of SolveBio by QuartzBio.
The continued growth of social and digital communications has ushered in new channels for the exchange of ideas and opinions. And now, these channels have given rise to new voices of influence—Digital Opinion Leaders (DOLs). To help pharma marketers identify and gain insights on DOLs in specific therapeutic areas, PRECISIONscientia has developed a powerful, web-based proprietary platform, DOL Map. The platform delivers an intuitive experience that summarizes each DOL’s impact, reach, and relevance to clients’ disease focus. DOL Map focuses on key components to find the right DOLs for any commercial brand or product in development: relevance, reach and audience engagement, impact on audience, and authenticity.
PRECISIONscientia’s DOL Map was named one of the most Innovative Products of 2022 by PM360 Magazine. Read the article HERE!
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
